

WHAT IS CLAIMED IS:

Sub
A, B, 1
5 1 A recombinant adenoviral vector encoding an pro-
apoptotic bax gene.

Sub
A, 2
10 2. A pharmaceutical composition, comprising the
adenoviral vector of claim 1 and a pharmaceutically acceptable
carrier.

Sub
A, B, 3
15 3. A method of treating an individual having a
pathophysiological state, comprising the step of administering to said
individual a pharmacologically effective dose of the composition of
claim 2.

20 4. The method of claim 3, wherein said
pathophysiological state is a neoplastic disease.

sub
A5

5. The method of claim 4, wherein said neoplastic disease is selected from the group consisting of breast cancer, colon cancer, ovarian cancer, glioma, osteosarcoma and haemopoietic cancers.

5

sub
A5

6. The method of claim 4, wherein said composition is administered in a dose of from about 0.1 mg/kg to about 100 mg/kg.

10

sub
A6

7. A method of treating an individual having ovarian cancer, comprising the step of administering to said individual a pharmacologically effective dose of a pharmaceutical composition, comprising a recombinant adenoviral vector encoding an pro-apoptotic *bax* gene and a pharmaceutically acceptable carrier.

15

8. The method of claim 7, wherein said composition is administered in a dose of from about 0.1 mg/kg to about 100 mg/kg.

20

sub
A₇ 5

[illegible]

10. The method of claim 9, wherein said composition is